NMNH is the reduced form of NMN, and preclinical studies suggest it can raise NAD+ more strongly and rapidly than NMN. But that does not mean NMNH has been proven better in humans.
NMN currently has the much larger peer-reviewed human evidence base. NMNH now has emerging controlled human data from a 90-day randomized trial, but those results were released as a 2026 preprint and have not yet completed peer review.5,6
The most accurate 2026 conclusion is:
NMNH looks more potent in cells and animals, while NMN remains the better-studied option in humans. No head-to-head human trial has established that NMNH produces better clinical outcomes than NMN.
NMN vs NMNH at a Glance
| Factor | NMN | NMNH |
|---|---|---|
| Full name | Nicotinamide mononucleotide | Reduced / dihydronicotinamide mononucleotide |
| Redox form | Oxidized | Reduced |
| NAD+ precursor | Yes | Yes |
| Human randomized trials | Multiple | One emerging controlled trial |
| Peer-reviewed human evidence | Substantial relative to NMNH | Very limited |
| Faster/larger NAD+ increase preclinically | Less than NMNH | Yes |
| Human superiority demonstrated | No | No |
| Short-term human safety evidence | Larger evidence base | Preliminary |
| Commercial formulation maturity | More established | Still developing |
What Is NMN?
NMN stands for nicotinamide mononucleotide.
It is an oxidized NAD+ precursor involved in the body's NAD+ biosynthesis pathways. NAD+ is a coenzyme involved in normal cellular metabolism and many enzyme-dependent reactions.
NMN has now been evaluated in multiple randomized human trials. Those studies have examined NAD-related biomarkers, physical function, insulin sensitivity, metabolic outcomes, and short-term safety.
A 2026 systematic review and meta-analysis included 15 randomized trials of oral NMN or NMN-related supplementation, making NMN's human evidence base considerably larger than NMNH's at this point.4
For the broader NMN overview, see What Is NMN?.
What Is NMNH?
NMNH is reduced nicotinamide mononucleotide, also called dihydronicotinamide mononucleotide.
It is chemically related to NMN but exists in a different redox state.
NMNH attracted research interest because early cell and animal studies showed that it could raise NAD+ more strongly than standard oxidized precursors such as NMN and nicotinamide riboside.1
That makes NMNH scientifically interesting—but a strong NAD+ increase in cells or mice does not establish superior human health outcomes.
Are NMN and NMNH the Same Thing?
No.
They are closely related compounds, but they are not chemically identical or biologically interchangeable.
A simple way to distinguish them is:
- NMN is the oxidized form.
- NMNH is the reduced form.
That difference affects how the molecules enter cellular metabolism and how strongly they influence the NAD+/NADH system.
What Does “Reduced” Mean?
In chemistry, “reduced” refers to the molecule's redox state.
NMNH carries additional reducing equivalents compared with oxidized NMN. That changes how it interacts with cellular redox metabolism.
It is common to describe NMNH casually as “NMN with extra hydrogen,” but that explanation is too simplistic to capture the metabolic difference.
The important point is that reduced and oxidized NAD+ precursors can enter metabolism differently and produce different downstream effects.
How Do NMN and NMNH Raise NAD+?
NMN
NMN participates in established NAD+ biosynthesis pathways and can be converted into NAD+ through NMN adenylyltransferase enzymes.
NMNH
Early NMNH research suggested a distinct metabolic route.
A 2021 study found that NMNH raised NAD+ through a pathway that was independent of the standard NRK and NAMPT pathways used by conventional oxidized NAD+ precursors.1
Other research has shown that NMNH can also influence NADH levels and broader cellular redox metabolism.2
So NMN and NMNH should not be treated as two labels for the same supplement.
What Did the First NMNH Studies Find?
A key 2021 study compared NMNH with NMN and NR in mammalian cells and mice.1
Researchers reported that NMNH:
- increased NAD+ more strongly than NMN or NR in cultured cells;
- produced a faster NAD+ increase;
- used a metabolic pathway distinct from standard NRK- and NAMPT-dependent pathways;
- and caused a rapid, sustained NAD+ rise in mouse blood and several tissues.
Those findings are why NMNH is sometimes described as a more potent NAD+ precursor.
But the study was preclinical.
Faster or larger NAD+ increases in cells and mice do not prove that NMNH is clinically better than NMN in humans.
NMNH Has Broader Metabolic Effects Than NMN
Another 2021 study found that NMNH did more than increase NAD+.2
It also:
- increased NADH;
- altered glycolysis;
- altered TCA-cycle metabolism;
- induced cell-cycle arrest;
- and suppressed cell growth in experimental systems.
Those effects should not automatically be labeled good or bad.
They show that NMNH can influence cellular metabolism more broadly than simply raising NAD+.
This is why the statement “NMNH raises more NAD+, therefore it must be better” is too simplistic.
What Did the 2026 Multi-Omics Study Find?
A 2026 study directly compared oxidized NAD+ precursors NMN and NR with the reduced forms NMNH and NRH in cultured mouse liver cells.3
The researchers used metabolomics, transcriptomics, and proteomics to examine the downstream cellular effects.
Reduced precursors produced substantially broader changes than oxidized NMN and NR.
NMNH and NRH:
- produced stronger changes in the NAD+ metabolome;
- affected more metabolites;
- changed expression of many more genes;
- produced broader protein-level changes;
- and triggered stress-related cellular responses not seen to the same degree with oxidized NMN and NR.3
For example, NMNH altered 31 measured metabolites significantly compared with eight after NMN treatment under the study conditions, and it produced far more differentially expressed genes than NMN.3
Importantly, the researchers did not interpret those broader effects as automatically beneficial.
They highlighted the possibility of both therapeutic and potentially undesirable effects from the wider cellular impact of reduced NAD+ precursors.
More powerful metabolic effects are not automatically better effects.
What Does Human Research Show About NMN?
NMN currently has the advantage when it comes to peer-reviewed human research.
Randomized trials have tested oral NMN across multiple doses and populations.
A 2026 systematic review and meta-analysis identified 15 randomized controlled trials, with daily doses ranging from 250 mg to 2,000 mg and study durations from 14 days to 24 weeks.4
The review found generally favorable short-term tolerability, with no clear increase in:
- overall adverse events;
- serious adverse events;
- withdrawals due to adverse events;
- or ALT and AST liver-enzyme abnormalities.4
But NMN should not be oversold either.
The same review did not find broad, consistent improvements in body weight, BMI, fasting glucose, HbA1c, lipid profiles, or systolic blood pressure.4
So NMN has the stronger human evidence base—but many broader commercial claims still go beyond what randomized trials consistently demonstrate.
What Did the First Controlled Human NMNH Trial Study?
A randomized, double-blind, placebo-controlled trial registered as NCT06889740 enrolled 80 healthy adults aged 40–65.5
Participants received one of four treatments for 90 days:
- placebo;
- 125 mg NMNH;
- 250 mg NMNH;
- or 500 mg NMNH.
The investigational ingredient was a reduced β-NMN calcium salt, or NMNH-Ca, rather than generic free NMNH.
The study evaluated:
- safety and tolerability;
- whole-blood NAD+;
- acute pharmacodynamic response;
- BMI;
- six-minute walking distance;
- phenotypic-age calculations;
- and quality-of-life measures.5
What Does the 2026 NMNH Human Preprint Report?
Results from the trial were posted as a medRxiv preprint in August 2026.6
The authors reported a dose-related increase in whole-blood NAD+ over 90 days.
Mean changes from baseline at Day 90 were:
| Group | Mean change in whole-blood NAD+ |
|---|---|
| Placebo | +2.33 μM |
| NMNH-Ca 125 mg | +8.22 μM |
| NMNH-Ca 250 mg | +15.85 μM |
| NMNH-Ca 500 mg | +39.90 μM |
The acute substudy also reported increases in whole-blood NAD+ after a single NMNH-Ca dose, with mean peak concentrations occurring at 12 hours.6
The preprint also described exploratory signals in:
- six-minute walking distance;
- blood phenotypic age;
- and several quality-of-life measures.
These findings are interesting, but they require important qualification.
Why the NMNH Human Results Are Still Preliminary
The NMNH-Ca report is currently a preprint and has not yet been peer reviewed.6
That means the findings have not completed the same external scientific review process as a published peer-reviewed clinical paper.
There are also several study-specific limitations:
- the study used one specific NMNH calcium-salt formulation;
- 69 of the 80 participants were men;
- all participants were Asian;
- the trial lasted 90 days;
- many of the functional outcomes were exploratory;
- and several authors were employees of the company that provided and developed the investigational product.6
The preprint itself describes the phenotypic-age, walking-distance, and quality-of-life findings as hypothesis-generating.
So they should not be presented as established NMNH benefits.
NMN vs NMNH: Which Raises NAD+ More?
In Cells and Mice
NMNH appears more potent.
Preclinical studies found faster and larger NAD+ increases with NMNH compared with NMN.1,2
In Humans
We do not yet have a winner.
The NMNH-Ca human trial compared NMNH-Ca with placebo—not with NMN.5,6
NMN has its own separate randomized human studies showing NAD-related biomarker effects.
There is currently no mature controlled human head-to-head trial demonstrating that NMNH raises NAD+ more effectively than NMN in people.
That is an important distinction between:
preclinical potency
and
proven human superiority.
NMN vs NMNH Benefits
| Potential area | NMN | NMNH |
|---|---|---|
| Raises NAD-related biomarkers | Supported by human studies | Preclinical + preliminary human evidence |
| Physical function | Studied in some human trials | Exploratory preprint signal |
| Metabolic outcomes | Mixed human evidence | Insufficient human evidence |
| Anti-aging | Not proven | Not proven |
| Human lifespan extension | Not proven | Not proven |
| Energy | Not guaranteed as a finished-product outcome | Not established clinically |
Calling one compound a “better anti-aging supplement” would go well beyond the current evidence.
NMN vs NMNH Side Effects and Safety
NMN Safety
NMN currently has the larger peer-reviewed human safety database.
The 2026 meta-analysis found no clear short-term increase in overall adverse events, serious adverse events, withdrawals due to adverse events, or liver-enzyme abnormalities across the randomized trials included.4
Long-term evidence remains more limited.
NMNH Safety
The 2026 NMNH-Ca preprint reported favorable short-term tolerability over 90 days.6
Six mild treatment-emergent adverse events were reported across the study:
- body pain;
- fever;
- and headache.
All resolved without treatment, and investigators did not consider them related to NMNH-Ca.
The preprint reported:
- no serious adverse events;
- no treatment-related adverse events;
- and no discontinuations because of adverse events.6
That is encouraging, but one preprint is not enough to define a reliable long-term NMNH safety profile.
For broader NMN safety context, see NMN Side Effects & Safety.
What Are the Common Side Effects of NMNH?
There is not yet enough peer-reviewed human evidence to define a reliable list of “common NMNH side effects.”
Claims that NMNH commonly causes nausea, headache, drowsiness, or another specific symptom should not be treated as established unless supported by appropriate human safety data.
The current controlled NMNH-Ca preprint did report isolated mild events such as headache, fever, and body pain, but investigators did not attribute those events to NMNH-Ca.6
Why Does NMNH Formulation Matter?
The first controlled human trial did not use generic free NMNH.
It used reduced β-NMN calcium salt, or NMNH-Ca.6
The study authors state that this calcium-salt formulation has greater stability and lower hygroscopicity than free NMNH and NMNH disodium salt.
That matters because reduced nicotinamide compounds can present different formulation and stability challenges from their oxidized counterparts.
Results from one stabilized NMNH-Ca formulation should therefore not automatically be applied to every commercial product labeled “NMNH.”
Is NMNH the Same as NAD+?
No.
They are related but different molecules.
- NMN is an oxidized NAD+ precursor.
- NMNH is a reduced NAD+ precursor.
- NAD+ is the coenzyme itself.
For the broader distinction between NAD+ and its precursor compounds, see NMN vs NR vs NAD+.
Is NMNH Better Than NMN?
That depends on what you mean by “better.”
If “better” means stronger NAD+ elevation in cells and mice:
If “better” means stronger peer-reviewed human evidence:
NMN currently has the advantage.
NMN has multiple randomized human trials and systematic reviews, while the first controlled NMNH-Ca human results are currently available as a preprint.4,6
If “better” means better clinical outcomes:
Neither has established superiority over the other.
There is no mature human head-to-head comparison showing that NMNH improves health outcomes more than NMN.
Which Would We Choose Based on the Evidence Today?
If the main criterion is the maturity of the human evidence base, NMN currently has the stronger case.
That does not prove NMNH is ineffective or inferior.
NMNH is an emerging reduced NAD+ precursor with:
- strong preclinical NAD+ effects;
- a distinct metabolic profile;
- and encouraging preliminary controlled human data.
What it does not yet have is the same depth of peer-reviewed human research as NMN.
For people comparing established NMN supplement formats, see NMN Supplements.
What About FDA and Regulatory Status?
Regulatory status and scientific effectiveness are separate questions.
The U.S. regulatory history around NMN has changed substantially in recent years and should not be used as evidence that NMN or NMNH is biologically superior.
For the updated regulatory timeline, see Why Is NMN Banned by FDA?.
Frequently Asked Questions
What is NMNH?
NMNH is reduced nicotinamide mononucleotide, also called dihydronicotinamide mononucleotide.
It is the reduced counterpart of NMN and can act as an NAD+ precursor.
What does NMNH stand for?
NMNH generally refers to reduced nicotinamide mononucleotide or dihydronicotinamide mononucleotide.
Are NMN and NMNH the same thing?
No.
NMN is the oxidized form, while NMNH is the reduced form. Their redox state and metabolic behavior differ.
What is the difference between NMN and NMNH?
The main differences are their redox state, metabolism, preclinical NAD+ potency, maturity of human evidence, and current formulation history.
NMNH has produced stronger NAD+ increases in preclinical research, while NMN has a substantially larger peer-reviewed human evidence base.
Which is better, NMN or NMNH?
No human trial has established overall clinical superiority.
NMNH looks more potent in preclinical NAD+ studies, while NMN currently has the stronger peer-reviewed human evidence base.
Is NMNH better than NMN?
Not proven in humans.
Cell and animal research suggests NMNH can raise NAD+ more strongly, but human head-to-head superiority has not been demonstrated.
Does NMNH raise NAD+ more than NMN?
In cells and mice, NMNH has produced larger and faster NAD+ increases than NMN.1,2
That has not yet been demonstrated in a controlled human NMN-vs-NMNH trial.
What are the benefits of NMNH?
The strongest current evidence is that NMNH can substantially increase NAD+ in preclinical research and that NMNH-Ca increased whole-blood NAD+ in a preliminary 90-day human trial.1,6
Broader claims about anti-aging, energy, longevity, or disease prevention remain unproven.
What are the side effects of NMNH?
There is not enough peer-reviewed human evidence to define a reliable common-side-effect profile.
The 90-day NMNH-Ca preprint reported no serious or treatment-related adverse events, but larger and longer peer-reviewed trials are still needed.6
Is NMNH safe?
Preliminary controlled human data suggest short-term NMNH-Ca use up to 500 mg/day was generally well tolerated for 90 days.6
That does not establish long-term safety or apply automatically to every NMNH formulation.
Is NMNH the same as NAD+?
No.
NMNH is a reduced precursor. NAD+ is the coenzyme itself.
Is NMNH more stable than NMN?
That cannot be answered universally.
Specific NMNH formulations can have different stability characteristics. The 2026 human trial used an NMNH calcium salt specifically described as more stable and less hygroscopic than free NMNH.6
What dose of NMNH has been studied in humans?
The 90-day controlled NMNH-Ca trial studied 125 mg, 250 mg, and 500 mg once daily.5,6
Those research doses should not automatically be interpreted as universal consumer dosing recommendations.
Does NMNH slow aging?
That has not been established.
The 2026 preprint included exploratory phenotypic-age measurements, but these findings are hypothesis-generating and do not prove that NMNH slows human aging.6
Should I take NMN or NMNH?
There is no universal answer.
If you prioritize a larger peer-reviewed human evidence base, NMN currently has the advantage. NMNH remains an emerging option with promising preclinical and preliminary human evidence but greater uncertainty.
Final Takeaway
NMN and NMNH are related NAD+ precursors, but they are not the same compound.
NMNH is the reduced form and has produced larger and faster NAD+ increases than NMN in preclinical studies.1,2
It also produces broader cellular metabolic effects, which may ultimately prove useful but also mean that “stronger” should not automatically be interpreted as “better.”3
NMN currently has the stronger peer-reviewed human evidence base, while NMNH now has encouraging—but still preliminary—controlled human data from a 2026 preprint.4,6
The most defensible conclusion today is:
NMNH appears more potent preclinically. NMN is better studied in humans. Clinical superiority of either compound over the other has not been established.
Compare Neurogan Health NMN Supplements.
References
- Zapata-Pérez R, Tammaro A, Schomakers BV, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB Journal. 2021;35(4):e21456. PMID: 33724555. doi:10.1096/fj.202001826R.
- Liu Y, Luo C, Li T, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. Journal of Proteome Research. 2021;20(5):2596–2606. PMID: 33793246. doi:10.1021/acs.jproteome.0c01037.
- Vinten KT, Schomakers BV, Denis S, et al. Reduced Versus Oxidized NAD+ Precursors Drive Distinct Transcriptomic, Proteomic, and Metabolic Profiles in Hepatocytes. FASEB Journal. 2026;40(4):e71582. PMID: 41701114. doi:10.1096/fj.202501925R.
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. PMID: 42514320. doi:10.3390/nu18142251.
- ClinicalTrials.gov. A Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants. NCT06889740. Study completed January 25, 2025.
- Li J, Wang Y, Liang Y, et al. Safety and Exploratory Efficacy of Reduced β-Nicotinamide Mononucleotide Calcium Salt (NMNH-Ca) in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. medRxiv. 2026. doi:10.64898/2026.08.11.26360226. Preprint; not peer reviewed.
